Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.

Related Articles
The Rosewood Foundation And Retina Foundation Of The Southwest Partner Up Again For “Keeping An Eye On Innovation” Series Retina Foundation Presents at Largest Retina Meeting in China Retina Foundation of the Southwest New Home in Dallas Retina Foundation of the Southwest/Rebion Selected As “Partner of the Year” Recently@Retina Newsletter October 2023